Physician profile
Mark B Taylor
NPI 1790766525
$12,992.61
in general payments reported to CMS, 2019-2025
31 companies · $1,805 in 2025
The $1,805 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $55.19 · 2021: $180 · 2022: $7,916 · 2023: $1,614 · 2024: $1,181 · 2025: $1,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,410 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,410.40 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $9,089.83 | 2019-2025 | Linzess, Viberzi, Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $641.79 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $567.80 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $445.36 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $408.23 | 2023-2025 | Ibsrela |
| Janssen Biotech, INC. | $268.17 | 2019-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $186.05 | 2025 | Rezdiffra |
| Qol Medical, LLC | $161.22 | 2023-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $130.60 | 2024 | |
| Lilly USA, LLC | $127.79 | 2024-2025 | Omvoh, Zepbound |
| Regeneron Healthcare Solutions, INC. | $108.23 | 2024-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $105.27 | 2019-2024 | Linzess |
| Pfizer INC. | $105.15 | 2023-2025 | |
| Gilead Sciences, INC. | $83.64 | 2022-2025 | |
| Braintree Laboratories, INC. | $78.47 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $75.57 | 2019-2023 | Rebyota |
| Fresenius Kabi USA, LLC | $64.92 | 2023-2024 | Idacio |
| Intercept Pharmaceuticals, INC. | $51.20 | 2023 | Ocaliva |
| Exact Sciences Corporation | $49.96 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $46.05 | 2024-2025 | Voquezna |
| Allergan, INC. | $22.09 | 2019 | |
| Bausch & Lomb Americas INC. | $20.96 | 2022 | |
| Genzyme Corporation | $20.74 | 2023 | |
| Smith+Nephew, INC. | $20.56 | 2023 | Pico |
| Intra-Sana Laboratories | $20.17 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Pentax of America, INC. | $18.53 | 2023 | Pentax Medical |
| Tempus Ai, INC | $16.39 | 2024 | Xt Cdx |
| Evoke Pharma, INC. | $15.64 | 2025 | |
| Boston Scientific Corporation | $15.03 | 2022 | |
| Merck Sharp & Dohme LLC | $13.99 | 2024 | Dificid |
| Shionogi INC | $13.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.